Business
Publication of Final Terms
Publication of Final Terms.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 5008A\n AstraZeneca PLC\n 02 June 2021\n \n \n \n \n 2 June 2021 07:00 BST\n \n \n \n \n \n \n \n \n \n Publication of Final Terms for \n \n \n €\n \n \n 800m bond offering\n \n \n \n \n \n The Final Terms, dated 1 June 2021, relating to the issue by AstraZeneca PLC of €800,000,000 of fixed rate notes with a coupon of 0.375%, maturing on 3 June 2029 (the \"Notes\") are available for viewing. \n \n The Notes will be issued under the $10,000,000,000 EMTN programme of AstraZeneca PLC and AstraZeneca Finance LLC. The Final Terms must be read in conjunction with the Base Prospectus dated 24 May 2021.\n \n \n \n \n To view the Final Terms for the Notes, please paste the following URL into the address bar of your browser: http://www.rns-pdf.londonstockexchange.com/rns/5008A_1-2021-6-1.pdf\n \n \n \n \n A copy of the above Final Terms will shortly be available for inspection at:\n \n \n https://data.fca.org.uk/#/nsm/nationalstoragemechanism\n \n \n \n \n \n AstraZeneca\n AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca. \n \n Contacts\n \n \n For details on how to contact the Investor Relations Team, please click \n \n here\n \n . For Media contacts, click \n \n here\n \n .\n \n \n \n \n \n \n \n \n Adrian Kemp\nCompany Secretary\n \n \n AstraZeneca PLC\n \n \n \n \n \n \n This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in ...